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309Abstracts
useful for employers who are interested in estimating productiv-
ity losses and in learning where to focus their energy to help stem
those losses.
PMD28
USING A WEB-PANEL TO AID DEFINITION OF A TARGET
PATIENT POPULATION TO ASSIST RISK MANAGEMENT
Eaton SC1, Cook SF2,Andrews EB1, Hollis KA1,Ameen VZ2,
Fehnel SE1
1RTI Health Solutions, Research Triangle Park, NC, USA;
2GlaxoSmithKline, Inc, Research Triangle Park, NC, USA
OBJECTIVES: To estimate the prevalence of IBS-D in a US pop-
ulation, and to evaluate patients’ self-reported severity of
episodes. Prior use of medications commonly used to alleviate
IBS symptoms and FS were also evaluated. METHODS: A two-
stage, population based, cross-sectional survey was conducted
from December 2001–February 2002. Data were collected from
U.S. participants via internet panel. Of the 31,829 person sam-
pling frame, 25,986 (82%) completed a screening questionnaire
to identify IBS and subtypes using ROME II criteria. A ques-
tionnaire was administered to IBS-D and alternating IBS (IBS-A)
cases to assess symptoms, medication history, and FS using the
Medical Outcomes Survey SF-36 instrument. RESULTS: Screen-
ing identiﬁed 1713 cases (6.6%) meeting Rome II criteria.
Among these, 1,380 cases had IBS-D (n = 901) and IBS-A (n =
453). A total of 1180 of the 1380 IBS-D and IBS-A cases com-
pleted questionnaires. Between 8–43% of the cases’ most recent
episode were considered severe depending upon various deﬁni-
tions of severity. Over 95% of cases reported taking OTC med-
ications, while 50% used prescription medications to treat IBS
symptoms. Functional status scores of respondents were sub-
stantially lower than national norms on all dimensions of the SF-
36. Individuals reporting their most recent episode as severe had
still further impaired levels of functioning. CONCLUSIONS:
This novel methodology and technology generated population-
based estimates of IBS-D in a short period of time and assisted
a drug sponsor in developing a risk management plan. The pro-
portion of survey respondents deﬁned as severe based on char-
acteristics of their most recent episode is in contrast to estimated
severity rates (~5%) in all IBS subtypes, based on physician
assessments. This is the ﬁrst study to evaluate FS in IBS at the
population level. Using this methodology, additional questions
may be posed to this IBS population.
SESSION II
ASTHMA/ALLERGY (including ARDS)
ASTHMA/ALLERGY (including ARDS)—Clinical
Outcomes Studies
PAA1
MEASURING THE IMPACT OF AN ASTHMA DISEASE
MANAGEMENT INTERVENTION ON PHARMACY AND 
IN-PATIENT SERVICE UTILIZATION IN A MANAGED CARE
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OBJECTIVE: To measure the impact of an asthma disease man-
agement intervention by comparing pharmacy and in-patient
service utilization during a six-month “pre” and “post” inter-
vention period. METHODS: Care 1st health plan enrollees, pre-
dominantly Medicaid members, were identiﬁed as having asthma
if they had any ER or in-patient claims with ICD-9 codes 493,
or a claim for short acting b2-agonists, or any anti-inﬂammatory
medications in the year prior to the start of the intervention.
Patients were mailed a baseline self-assessment and QoL survey.
Patients were stratiﬁed into four asthma severity categories based
upon claims data; mild-intermittent, mild-persistent, moderate-
persistent, and severe-persistent. Respondents with mild-
intermittent or mild-persistent asthma were enrolled in a
program consisting primarily of educational material delivered
via mail. Respondents and a small number of non-respondents
with moderate-persistent or severe-persistent asthma were
referred to a telephonic case management program. Patients not
responding to the survey, and not enrolled into either of the two
interventions, served as the control group. This analysis is limited
to the 1522 patients with continuous eligibility for the entire
study period, and with at least one pharmacy claim in each of
the two 6-month periods. RESULTS: The mean age of the sample
was 15 years, 47% were female, and 64% were of Hispanic
origin. Overall, the percentage of patients with high b2-agonist
use (4 + claims) decreased from 27.5% in the “pre” to 22.2%
in the “post” period (P < 0.001). Use of oral steroids decreased
from 35% to 28.7%, and inhaled steroids increased from 28.8%
to 33.6% (P < 0.001). Overall percentage of patients with in-
patient hospitalization decreased from 2.6% to 1.1% (P < 0.01).
CONCLUSION: Data from this evaluation provides strong evi-
dence that the comprehensive asthma disease management
program was successful in improving the quality of care provided
to members, and cost-effective due to the observed reduction in
costly inpatient services.
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THE PREVALENCE OF INAPPROPRIATE USE OF SHORT-
ACTING ASTHMA MEDICATION
Hong SH
University of Arkansas for Medical Sciences, Little Rock, AR, USA
OBJECTIVES: The aims of this study were to estimate what
portion of asthma patients are using quick-acting asthma med-
ications inappropriately and to examine how the inappropriate
use varies with age and sex. METHODS: Prescribed medicine
data of 1996–2000 from the Medical Expenditure Panel Survey
(MEPS) are retrospectively analyzed. The survey is on-going
project, sponsored by the Agency for Health care Research and
Quality. Non-institutionalized U.S. citizens of 5 or older who had
used quick-acting asthma relievers in a given year were identi-
ﬁed and further classiﬁed as “inappropriate users” if high doses
of short-acting beta-agonists were taken in conjunction with low
doses of inhaled corticosteroids. RESULTS: During the period of
1996–2000, a total of 2390 subjects reported that they had used
quick-acting asthma relievers per year. Of those, 284 (11.88%)
were 65 years of age or older and 862 (36.07%) were ﬁve
through 17 years of age. The remaining 1244 (52.45%) were 18
through 64 years of age. More than half of the subjects were
females (59.21%). About 6 percent (95% CI: 5.07–6.87%) of
the users of quick-acting asthma relievers were using the med-
ication inappropriately. Asthma patients with 65 years of age or
older were subject to a higher risk of medication misuse (9.09 ±
2.32%). Young children with ages of 5 through 17 years were
subject to a lower risk (4.16 ± 0.93%). Although males were
subject to a slightly lower risk than females (95% CI:
4.10–7.87% vs. 5.19–8.80%), the difference was not statistically
signiﬁcant. CONCLUSIONS: Despite the existence of national
guidelines on the proper use of shorting-acting asthma inhalers,
asthma patients who use short-acting asthma inhalers are at a
substantial risk of inappropriate use. Future national policies
should address ways of improving patient compliance in the use
of shorting acting asthma inhalers.
